Csenge Advisory Group Novavax Inc Transaction History

Csenge Advisory Group

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	BUY	$36.28 - $75.29 $39,908 - $82,819	1,100 Added 32.53%	4,482 $231,000
Q1 2022 May 09, 2022	BUY	$69.73 - $142.9 $64,848 - $132,897	930 Added 37.93%	3,382 $249,000
Q4 2021 Feb 10, 2022	SELL	$134.56 - $217.97 $160,799 - $260,474	-1,195 Reduced 32.77%	2,452 $529,000
Q3 2021 Oct 20, 2021	BUY	$177.8 - $270.58 $212,471 - $323,343	1,195 Added 48.74%	3,647 $662,000
Q1 2021 Apr 28, 2021	BUY	$112.98 - $319.93 $34,119 - $96,618	302 Added 14.05%	2,452 $441,000
Q3 2020 Nov 09, 2020	BUY	$79.44 - $178.51 $170,796 - $383,796	2,150 New	2,150 $231,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

Stay updated on Csenge Advisory Group with notifications on news.